Crum Demetris D 4

What Happened

• Demetris D. Crum, EVP and Chief HR Officer of AbbVie, reported awards on Feb 18, 2026: two performance-vesting restricted stock unit (RSU) releases totaling 2,460 shares (1,216 and 1,244) and a derivative award shown as 13,406 shares (an employee stock option). All items are reported with a $0 cash price because these are compensation awards/option grants, not open-market purchases or sales. The RSU releases were certified by the Compensation Committee and the shares are scheduled to be issued on Feb 28, 2026.

Key Details

• Transaction date: 2026-02-18; reported/filed: 2026-02-20 (timely filing).
• Reported prices/values: $0.00 for each award/derivative (compensation grants).
• RSUs released: 1,216 and 1,244 shares (total 2,460) — awarded under performance-vesting RSU grants from Feb 15, 2024 and Feb 13, 2025; issuance set for Feb 28, 2026 (see F1, F2).
• Option/derivative: 13,406-share employee stock option granted (see F3); becomes exercisable in annual increments of 4,469 on 2/18/2027, 4,469 on 2/18/2028 and 4,468 on 2/18/2029.
• Shares owned after transaction: not specified in the excerpt provided.
• Filing timeliness: filed Feb 20 for Feb 18 transactions — appears timely (not marked late).

Context

• These entries are compensation-related awards/releases, not market purchases or sales; awards reported at $0 reflect grant/vesting, not a cash transaction. Performance RSUs were released after Certification of performance goals tied to a relative return-on-equity measure. The option is a standard employee grant with multi-year vesting; no indication in this filing that any shares were sold immediately.